Lymphoid Malignancies Clinical Trial
Official title:
Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With Lymphoid Malignancies Undergoing Allogeienc Stem Cell Transplantation
Allogeneic stem cell transplantation is potential curative therapy for adult lymphoid malignancies. Based on our previous study, the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity and transplantation mortality and long-term survival is comparable to most data reported with slightly higher relapse rate particularly for patients in CR2. In this study, the investigators aim to further improve the conditioning with Fludarabine + iv-BU and to use CTX after stem cell transfusion as consolidation for lymphoid malignancies and graft-versus-host disease (GVHD) prophylaxis.
Patients with adult lymphoid malignancies received conditioning with Fludarabine + iv-BU. The GVHD was consisting of D+3 and D+4 CTX after stem cell transfusion. CSA will be added for all patients after D+5. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00383994 -
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
|
Phase 1 | |
Terminated |
NCT01013818 -
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Recruiting |
NCT04329728 -
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT01998035 -
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01705847 -
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT00406809 -
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02739360 -
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
|
Phase 4 | |
Terminated |
NCT00992732 -
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
|
Phase 2 | |
Active, not recruiting |
NCT02452697 -
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
|
Phase 2 | |
Not yet recruiting |
NCT06047886 -
CD34 Selection Using the Automated CliniMACS Prodigy
|
Phase 1 | |
Completed |
NCT02181478 -
Intra-Osseous Co-Transplant of UCB and hMSC
|
Early Phase 1 | |
Terminated |
NCT01596127 -
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
|
Phase 1/Phase 2 | |
Completed |
NCT00820508 -
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
|
Phase 1 | |
Recruiting |
NCT05371054 -
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00529438 -
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT00508807 -
RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT02091063 -
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 |